The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1445
Luliconazole Cream (Luzu) for Tinea Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved luliconazole (Luzu Cream, 1% – Valeant) for treatment of tinea pedis, tinea cruris, and tinea corporis infections.

DRUGS FOR TINEA PEDIS — Tinea pedis is the most common form of tinea infection. It is generally treated with a topical allylamine, benzylamine, or imidazole antifungal for 4 weeks (see Table 1). Allylamines are more active in vitro than imidazoles against the dermatophytes that cause the disease, but cure rates for allylamines, benzylamines, and imidazoles have generally been similar. Cure rates have been lower with tolnaftate, and nystatin is not effective. Relapse is common with all of these drugs.

PHARMACOLOGY — Maximum plasma concentrations of luliconazole were low but measurable after topical application of about 3.5 grams of cream daily for 15 days in patients with moderate to severe tinea ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Luliconazole Cream (Luzu) for Tinea Infections
Article code: 1445b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian